Hubei Jumpcan Pharmaceutical Co., Ltd. (SHA:600566)
China
· Delayed Price · Currency is CNY 26.98
+0.37 (1.39%)
May 13, 2025, 3:00 PM CST
SHA:600566 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 8,017 | 9,638 | 8,976 | 7,618 | 6,151 | Upgrade
|
| Other Revenue | - | 16.51 | 19.87 | 13 | 14.25 | Upgrade
|
| Revenue | 8,017 | 9,655 | 8,996 | 7,631 | 6,165 | Upgrade
|
| Revenue Growth (YoY) | -16.96% | 7.32% | 17.90% | 23.77% | -11.17% | Upgrade
|
| Cost of Revenue | 1,664 | 1,784 | 1,537 | 1,277 | 1,130 | Upgrade
|
| Gross Profit | 6,353 | 7,871 | 7,459 | 6,354 | 5,035 | Upgrade
|
| Selling, General & Admin | 3,387 | 4,379 | 4,477 | 4,031 | 3,300 | Upgrade
|
| Research & Development | 444.78 | 464.4 | 553.3 | 523.44 | 243.75 | Upgrade
|
| Other Operating Expenses | 102.04 | 146.24 | 138.81 | 120.9 | 99.9 | Upgrade
|
| Operating Expenses | 3,934 | 4,987 | 5,205 | 4,683 | 3,650 | Upgrade
|
| Operating Income | 2,420 | 2,884 | 2,254 | 1,671 | 1,385 | Upgrade
|
| Interest Expense | - | -17.58 | -30.41 | -34.9 | -33.03 | Upgrade
|
| Interest & Investment Income | 83.54 | 357.81 | 183.21 | 171.42 | 83.03 | Upgrade
|
| Other Non Operating Income (Expenses) | 378.44 | -0.83 | -1.2 | -0.41 | -0.58 | Upgrade
|
| EBT Excluding Unusual Items | 2,882 | 3,223 | 2,405 | 1,807 | 1,435 | Upgrade
|
| Gain (Loss) on Sale of Investments | 99.2 | 14.6 | -7.32 | 114.55 | 20.94 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.2 | 0.13 | 5.22 | 0.65 | 3.35 | Upgrade
|
| Asset Writedown | -2.88 | -1.09 | -0.53 | -0.42 | -0.77 | Upgrade
|
| Other Unusual Items | - | 60.42 | 105.09 | 28.96 | 25.37 | Upgrade
|
| Pretax Income | 2,978 | 3,297 | 2,508 | 1,950 | 1,484 | Upgrade
|
| Income Tax Expense | 441.54 | 470.03 | 336.2 | 233.22 | 206.29 | Upgrade
|
| Earnings From Continuing Operations | 2,537 | 2,827 | 2,172 | 1,717 | 1,277 | Upgrade
|
| Minority Interest in Earnings | -5.15 | -4.28 | -0.97 | 1.96 | - | Upgrade
|
| Net Income | 2,532 | 2,823 | 2,171 | 1,719 | 1,277 | Upgrade
|
| Net Income to Common | 2,532 | 2,823 | 2,171 | 1,719 | 1,277 | Upgrade
|
| Net Income Growth | -10.32% | 30.04% | 26.27% | 34.60% | -21.30% | Upgrade
|
| Shares Outstanding (Basic) | 917 | 916 | 890 | 886 | 835 | Upgrade
|
| Shares Outstanding (Diluted) | 917 | 916 | 908 | 900 | 835 | Upgrade
|
| Shares Change (YoY) | 0.08% | 0.91% | 0.91% | 7.82% | 2.36% | Upgrade
|
| EPS (Basic) | 2.76 | 3.08 | 2.44 | 1.94 | 1.53 | Upgrade
|
| EPS (Diluted) | 2.76 | 3.08 | 2.39 | 1.91 | 1.53 | Upgrade
|
| EPS Growth | -10.39% | 28.87% | 25.13% | 24.84% | -23.12% | Upgrade
|
| Free Cash Flow | 2,002 | 3,162 | 2,377 | 1,646 | 1,352 | Upgrade
|
| Free Cash Flow Per Share | 2.18 | 3.45 | 2.62 | 1.83 | 1.62 | Upgrade
|
| Dividend Per Share | - | 1.300 | 0.880 | 0.680 | 0.450 | Upgrade
|
| Dividend Growth | - | 47.73% | 29.41% | 51.11% | -63.41% | Upgrade
|
| Gross Margin | 79.25% | 81.52% | 82.91% | 83.27% | 81.67% | Upgrade
|
| Operating Margin | 30.18% | 29.87% | 25.05% | 21.89% | 22.47% | Upgrade
|
| Profit Margin | 31.58% | 29.24% | 24.13% | 22.53% | 20.72% | Upgrade
|
| Free Cash Flow Margin | 24.97% | 32.76% | 26.42% | 21.57% | 21.93% | Upgrade
|
| EBITDA | 2,726 | 3,180 | 2,561 | 1,964 | 1,666 | Upgrade
|
| EBITDA Margin | 34.01% | 32.94% | 28.47% | 25.74% | 27.03% | Upgrade
|
| D&A For EBITDA | 306.7 | 296.78 | 307.14 | 293.13 | 280.95 | Upgrade
|
| EBIT | 2,420 | 2,884 | 2,254 | 1,671 | 1,385 | Upgrade
|
| EBIT Margin | 30.18% | 29.87% | 25.05% | 21.89% | 22.47% | Upgrade
|
| Effective Tax Rate | 14.83% | 14.26% | 13.41% | 11.96% | 13.91% | Upgrade
|
| Revenue as Reported | - | 9,655 | 8,996 | 7,631 | 6,165 | Upgrade
|
Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.